Across TCGA pan-cancer cohorts, TCEAL9 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated TCEAL9 data layer compared with 3 for mutation status and 4 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TCEAL9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TCEAL9 expression acts as an unfavorable survival marker, although some lineages such as OV and THCA show a favorable association.
HNSC, KIRP, and STAD are the cancer types where TCEAL9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.